Physician profile
Stephen Lewellis
NPI 1891152641
$73,311.55
in general payments reported to CMS, 2019-2025
19 companies · $15K in 2025
The $15K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2021: $58.78 · 2022: $446 · 2023: $23K · 2024: $35K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $27K · Travel and Lodging: $9,647 · Food and Beverage: $4,050 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,210.00 |
| Consulting Fee | $26,620.56 |
| Travel and Lodging | $9,647.11 |
| Food and Beverage | $4,049.80 |
| Education | $163.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58,159.83 | 2022-2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $5,599.86 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $3,150.98 | 2023-2025 | Dupixent |
| Genzyme Corporation | $2,341.01 | 2021-2025 | |
| Botanix Sb INC | $1,429.53 | 2025 | Sofdra |
| Janssen Biotech, INC. | $507.95 | 2022-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $495.09 | 2023-2025 | Odomzo, Blu-U |
| Abbvie INC. | $428.75 | 2021-2025 | |
| Pfizer INC. | $290.99 | 2019-2024 | |
| Dermavant Sciences, INC. | $284.57 | 2023-2024 | Vtama |
| Ucb, INC. | $214.98 | 2024-2025 | Bimzelx |
| Organon LLC | $130.39 | 2025 | Vtama, Hadlima |
| Lilly USA, LLC | $62.09 | 2023 | Olumiant, Taltz |
| Leo Pharma INC. | $52.45 | 2025 | Anzupgo |
| Incyte Corporation | $49.34 | 2023-2024 | Opzelura |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.15 | 2025 | |
| Amgen INC. | $35.31 | 2022 | |
| Arcutis Biotherapeutics, INC. | $20.92 | 2023 | |
| Biocon Biologics INC | $19.36 | 2025 | Yesintek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lewellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.